A. Gringeri

发表

Immune tolerance induction in patients with haemophilia a and inhibitors: effectiveness and cost analysis in an European Cohort (The ITER Study)

P. Cortesi, L. Mantovani, A. Rocino, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

Management of bleeding disorders in children

E. Berntorp, A. Gringeri, C. Escuriola, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Understanding FVIII/VWF complex – report from a symposium of XXIX WFH meeting 2010

J. Oldenburg, A. Federici, N. Ewing, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Factor VIII safety: plasma-derived versus recombinant products.

A. Gringeri, 2011, Blood transfusion = Trasfusione del sangue.

Pharmacotherapy of haemophilia A

A. Gringeri, M. Muça-Perja, L. Mangiafico, 2011, Expert opinion on biological therapy.

Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma‐derived or recombinant factor VIII concentrates: a systematic review

A. Iorio, M. Marcucci, E. Santagostino, 2010, Journal of thrombosis and haemostasis : JTH.

Special lectures in haemophilia management

K. High, A. Batorova, A. Gringeri, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

European Association for Haemophilia and associated disorders ( EHAD ) European principles of haemophilia care

J. Astermark, W. Schramm, R. Lassila, 2008 .

European principles of haemophilia care

J. Astermark, K. Fischer, W. Schramm, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.

J. Astermark, D. Dimichele, S. Donfield, 2007, Blood.

Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma‐product exposed toddlers)

P. Mannucci, E. Santagostino, F. Peyvandi, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Immunogenicity of factor VIII concentrates in patients with hemophilia: a randomized clinical trial is warranted.

P. Mannucci, A. Gringeri, 2007, Blood.

Current use of by‐passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors

L. Mantovani, J. Astermark, H. M. van den Berg, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma‐derived solvent‐detergent factor VIII concentrate

A. Gringeri, G. Tagariello, P. Mannucci, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors

L. Mantovani, J. Astermark, H. M. van den Berg, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Response to Larson

A. Gringeri, 2005 .

Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors

P. Mannucci, A. Gringeri, P. Mannucci, 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain‐deleted recombinant factor VIII

M. Morfini, E. Santagostino, P. Mannucci, 2004, British journal of haematology.

112 Quality of Life in

A. Gringeri, H. V. Mackensen, 2010 .

Transmission of Hepatitis A to Patients with Hemophilia by Factor VIII Concentrates Treated with Organic Solvent and Detergent To Inactivate Viruses

S. Emerson, P. Mannucci, R. Purcell, 1994, Annals of Internal Medicine.

Randomized double‐blind, placebo‐controlled trial of twice‐daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1

A. Gringeri, P. Mannucci, Y. Laurian, 1994 .

Shorter survival of SDF1-3'A/3'A homozygotes linked to CD4+ T cell decrease in advanced human immunodeficiency virus type 1 infection.

G. Pantaleo, A. Lazzarin, H. Sheppard, 2000, The Journal of infectious diseases.

Shorter Survival of SDF 1-3 ′ A / 3 ′ A Homozygotes Linked to CD 4 + T Cell Decrease in Advanced Human Immunodeficiency Virus Type 1 Infection

G. Pantaleo, A. Lazzarin, H. Sheppard, 2022 .

Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo.

P. Mannucci, D. Brettler, H. ten Cate, 1992, Blood.

Quality of life assessment in clinical practice in haemophilia treatment

L. Mantovani, A. Gringeri, S. Mackensen, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Low risk of transmission of hepatitis E virus by large-pool coagulation factor concentrates

A. Zanetti, E. Santagostino, A. Gringeri, 1994, The Lancet.

Low risk of transmission of the human immunodeficiency virus by a solvent‐detergent‐treated commercial factor VIII concentrate

G. Mariani, A. Zanetti, M. Morfini, 1992, Journal of medical virology.

The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophilic males: an international, multicenter study.

J. Rasko, P. Mannucci, D. Brettler, 1992, Blood.

Quality‐of‐life differences between prophylactic and on‐demand factor replacement therapy in European haemophilia patients

P. Giangrande, B. Kroner, W. Schramm, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

Safety and effectiveness of raltegravir in patients with haemophilia and anti‐HIV multidrug resistance

S. Riva, A. Gringeri, L. Mangiafico, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Progression to AIDS among Italian HIV‐seropositive haemophiliacs

P. Mannucci, F. Chiarotti, A. Gringeri, 1991, AIDS.

Immune Status of Asymptomatic HIV-Infected Hemophiliacs: Randomized, Prospective, Two-Year Comparison of Treatment with a High-Purity or an Intermediate-Purity Factor VIII Concentrate

P. Mannucci, M. Morfini, N. Ciavarella, 1992, Thrombosis and Haemostasis.

Parotid and whole saliva in the prediction of serum total and free phenytoin concentrations

I. Shoulson, A. Gringeri, C. Cook, 1978, Clinical pharmacology and therapeutics.

Effect of halofenate on the serum binding of phenytoin.

A. Gringeri, W. Wardell, F. Karch, 1977, British journal of clinical pharmacology.

Relationship between Factor VII Activity and Clinical Efficacy of Recombinant Factor VIIa Given by Continuous Infusion to Patients with Factor VIII Inhibitors

M. Morfini, E. Santagostino, A. Rocino, 2001, Thrombosis and Haemostasis.

High prevalence of serum cryoglobulins in multitransfused hemophilic patients with chronic hepatitis C.

E. Santagostino, A. Gringeri, M. Muça-Perja, 1998, Blood.

High Prevalence of Serum Cryoglobulins in Multitransfused Hemophilic Patients With Chronic Hepatitis C

E. Santagostino, P. Mannucci, A. Gringeri, 1998 .

An innovative outcome-based care and procurement model of hemophilia management

L. Valentino, R. Crea, A. Gringeri, 2016, Expert review of pharmacoeconomics & outcomes research.

Identification of immunodominant epitopes in inactivated Tat-vaccinated healthy and HIV-1-infected volunteers.

D. Noonan, A. Albini, S. Ferrini, 2003, Journal of acquired immune deficiency syndromes.

Quality of life in hemophilia

A. Gringeri, S. Mackensen, 2007 .

infections in multitransfused hemophilic patients Serum hepatitis B virus DNA detects cryptic hepatitis B virus

G. Colucci, P. Mannucci, A. Gringeri, 2011 .

Clinical outcomes and resource utilization associated with haemophilia care in Europe

P. Giangrande, B. Kroner, W. Schramm, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement

A. Iorio, E. Iserman, J. Oldenburg, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

A multicenter pharmacokinetic study of the B‐domain deleted recombinant factor VIII concentrate using different assays and standards

P. Mannucci, M. Morfini, S. Cinotti, 2003, Journal of thrombosis and haemostasis : JTH.

How I treat inhibitors in haemophilia

M. Makris, R. d'Oiron, C. Hay, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Inhibitors in haemophilia A: the role of VWF/FVIII concentrates – a meeting report

S. Kaveri, A. Gringeri, W. Kreuz, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response

P. Mannucci, M. Mazzucconi, A. Gringeri, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Prevalence of Infection with the Hepatitis C Virus among Italian Hemophiliacs before and after the Introduction of Virally Inactivated Clotting Factor Concentrates: A Retrospective Evaluation

P. Mannucci, M. Morfini, N. Ciavarella, 1994, Vox sanguinis.

VWF/FVIII concentrates in high‐risk immunotolerance: the RESIST study

A. Gringeri, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

Frequency of a mutated CCR-5 allele (delta32) among Italian healthy donors and individuals at risk of parenteral HIV infection.

L. Chieco‐Bianchi, V. Coppola, E. Santagostino, 1999, AIDS research and human retroviruses.

Consensus perspectives on prophylactic therapy for haemophilia: summary statement

J. Astermark, P. Giangrande, R. Ljung, 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

Effect of clotting factors concentrates on lymphocyte and neutrophil function in vitro

F. Dallegri, A. Gringeri, F. Puppo, 2003, Thrombosis and Haemostasis.

A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation

M. Morfini, E. Santagostino, Mark P Smith, 2003, British journal of haematology.

Diethyldithiocarbamate inhibition of murine bone marrow toxicity caused by cis-diamminedichloroplatinum(II) or diammine-(1,1-cyclobutanedicarboxylato)platinum(II).

P. Keng, A. Gringeri, R. Borch, 1988, Cancer research.

Home treatment with recombinant activated factor VII in patients with factor VIII inhibitors: the advantages of early intervention

E. Santagostino, A. Gringeri, P. Mannucci, 1999, British journal of haematology.

Melanocortin peptides inhibit production of proinflammatory cytokines in blood of HIV-infected patients

J. M. Lipton, E. Santagostino, A. Catania, 1998, Peptides.

Lipid-based amphotericin B in the treatment of cryptococcosis

A. Tortorano, A. Gringeri, M. Viviani, 1994, Infection.

Long‐term safety and feasibility of arteriovenous fistulae as vascular accesses in children with haemophilia: a prospective study

P. Mannucci, E. Santagostino, P. Mannucci, 2003, British journal of haematology.

Prophylactic Dosing of Anti Inhibitor Coagulant Complex (FEIBA) Reduces Bleeding Frequency In Hemophilia A Patients with Inhibitors Results of the Pro FEIBA Study

C. Leissinger, C. Négrier, E. Berntorp, 2010 .

Tat toxoid as a component of a preventive vaccine in seronegative subjects.

A. Burny, E. Santagostino, J. Zagury, 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Failure of recombinant activated factor VII during surgery in a hemophiliac with high-titer factor VIII antibody.

E. Santagostino, P. Mannucci, A. Gringeri, 1991, Haemostasis.

Markers of Hypercoagulability in Patients with Hemophilia B Given Repeated, Large Doses of Factor IX Concentrates during and after Surgery

P. Mannucci, E. Santagostino, K. Bauer, 1994, Thrombosis and Haemostasis.

Intramuscular anti‐D immunoglobulins for home treatment of chronic immune thrombocytopenic purpura

P. Mannucci, E. Santagostino, A. Gringeri, 1992, British journal of haematology.

Low incidence of bleeding from HIV‐related thrombocytopenia in drug addicts and hemophiliacs: Implications for therapeutic strategies

T. Barbui, A. Lazzarin, A. Gringeri, 1990, European journal of haematology.

Accelerated schedule of hepatitis B vaccination in patients with hemophilia

E. Santagostino, P. Mannucci, A. Rocino, 1993, Journal of medical virology.

Long‐term treatment with zidovudine in patients with human immunodeficiency virus (HIV)‐associated thrombocytopenia: Modes of response and correlation with markers of HIV replication

A. Lazzarin, P. Cinque, E. Santagostino, 1993, European journal of haematology.

Non‐genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report

J. Astermark, P. Holme, K. Fijnvandraat, 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat toxoid.

E. Santagostino, J. Zagury, A. Gringeri, 1998, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate

P. Mannucci, E. Santagostino, K. Bauer, 1991, British journal of haematology.

PCR analysis of HIV‐1 sequences and differential immunological features in seronegative and seropositive haemophiliacs

C. Peschle, G. Mariani, U. Testa, 1992, British journal of haematology.

Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients.

W. Blattner, A. Burny, E. Santagostino, 1998, Journal of human virology.

Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine.

W. Blattner, A. Burny, J. Zagury, 1998, Journal of human virology.

Current and future approaches to overcoming the challenges of hemophilia treatment personalization

A. Gringeri, J. Doralt, K. Steinitz-Trost, 2017 .

High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal transaminase levels.

P. Mannucci, A. Gringeri, M. Colombo, 1990, Annals of internal medicine.

Serum hepatitis B virus DNA detects cryptic hepatitis B virus infections in multitransfused hemophilic patients.

G. Colucci, P. Mannucci, A. Gringeri, 1990, Blood.

Inhibitors to Factor VIII in a Family with Mild Hemophilia: Molecular Characterization and Response to Factor VIII and Desmopressin

P. Mannucci, E. Santagostino, A. Gringeri, 1995, Thrombosis and Haemostasis.

A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high‐titre inhibitors

C. Leissinger, J. Goudemand, P. Monahan, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

State of Care for Hemophilia in Pediatric Patients

E. Santagostino, P. Mannucci, A. Gringeri, 2002, Paediatric drugs.

Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors

K. Fischer, R. Klamroth, A. Gringeri, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Modeling costs and outcomes associated with a treatment algorithm for problem bleeding episodes in patients with severe hemophilia a and high-titer inhibitors.

C. Leissinger, E. Gomperts, G. Young, 2011, American health & drug benefits.

The application of bypassing‐agent prophylaxis in haemophilia A patients with inhibitors: a meeting report

L. Valentino, C. Leissinger, V. Blanchette, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

A multicenter controlled, randomized, open trial of interferon alpha2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Hepatitis Study Group of the Association of Italian Hemophilia Centers.

P. Pontisso, M. Morfini, E. Santagostino, 1997, Blood.

Health status and health‐related quality of life of children with haemophilia from six West European countries

M. Bullinger, G. Auerswald, K. Khair, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

“ADAMTS13 levels in a plasma-derived FVIII concentrate: A potential therapeutic option for patients with congenital thrombotic thrombocytopenic purpura”

R. Crea, A. Gringeri, P. Mathew, 2022, Thrombosis Update.

Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data.

P. Cortesi, L. Mantovani, M. Rota, 2017, Blood advances.

Global Post-Authorization Safety Surveillance Study: real-world data on prophylaxis and on-demand treatment using FEIBA (an activated prothrombin complex concentrate)

C. Négrier, F. Baghaei, A. Gringeri, 2016, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Ultrasonography of haemophilic arthropathy

S. Riva, A. Gringeri, M. Muça-Perja, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)

L. Mantovani, P. Mannucci, A. Gringeri, 2011, Journal of thrombosis and haemostasis : JTH.

Development of novel treatment options for patients with haemophilia

H. Ehrlich, A. Loew-Baselli, A. Gringeri, 2013, Hämostaseologie.

The burden of bleeding in haemophilia: is one bleed too many?

A. Gringeri, B. Ewenstein, A. Reininger, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

From theory to practice: applying current clinical knowledge and treatment strategies to the care of hemophilia a patients with inhibitors.

Alessandro Gringeri, Jan Astermark, J. Astermark, 2008, Blood reviews.

Tertiary prophylaxis in adults: is there a rationale?

T. Lambert, L. Aledort, A. Gringeri, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients

C. Leissinger, G. Dolan, T. Lambert, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Prospective controlled studies on prophylaxis: an Italian approach

A. Gringeri, 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

Unresolved issues in prophylaxis

J. Astermark, C. Leissinger, V. Blanchette, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

P. Cortesi, L. Mantovani, C. Leissinger, 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

Pain management in patients with haemophilia: a European survey

R. Klamroth, K. Holstein, M. Carvalho, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

the COCIS Study Group Cost of care and quality of life in hemophilia complicated by inhibitors

L. Mantovani, P. Mannucci, L. Scalone, 2013 .

by inhibitors: the COCIS Study Group Cost of care and quality of life for patients with hemophilia complicated

L. Mantovani, P. Mannucci, L. Scalone, 2013 .

Haemophilia Care in Europe: the ESCHQoL study

L. Mantovani, M. Bullinger, A. Crispin, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

A. Gringeri, S. von Mackensen, P. Mannucci, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy

P. Mannucci, E. Santagostino, M. Franchini, 2009, Journal of thrombosis and haemostasis : JTH.

Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors

L. Mantovani, P. Mannucci, L. Scalone, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group.

L. Mantovani, P. Mannucci, L. Scalone, 2003, Blood.

Patients’, physicians’, and pharmacists’ preferences towards coagulation factor concentrates to treat haemophilia with inhibitors: results from the COHIBA Study

L. Mantovani, L. Scalone, A. Gringeri, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

J. Epstein, L. Valentino, A. Gringeri, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Continuous infusion in haemophilia: current practice in Europe

C. Hermans, P. Holme, K. Fijnvandraat, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Identifying non‐responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition

C. Négrier, G. Young, P. Collins, 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

Prophylactic bypassing agent use before and during immune tolerance induction in patients with haemophilia A and inhibitors to FVIII

L. Valentino, K. Khair, A. Gringeri, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Prophylaxis in Inhibitor Patients

A. Gringeri, 2014 .

The FEIBA® NovoSeven® Comparative Study (FENOC)—A Randomized Evaluation of By-Passing Agents in Hemophilia Complicated by Inhibitors.

J. Astermark, S. Donfield, E. Berntorp, 2005 .

Consensus perspectives on surgery in haemophilia patients with inhibitors: summary statement

J. Goudemand, C. Négrier, E. Rodríguez‐Merchán, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Combination/Sequential Use of Bypassing Agents

A. Gringeri, 2011 .

Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors.

P. Cortesi, L. Mantovani, C. Leissinger, 2011, The New England journal of medicine.

Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate.

P. Mannucci, K. Bauer, R. Rosenberg, 1990, Blood.

Therapeutic choices for patients with hemophilia and high‐titer inhibitors

M. Poon, L. Aledort, E. Berntorp, 2001, American journal of hematology.

Bypassing agent regimens and costs for prophylaxis in patients with inhibitors

A. Gringeri, 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

Pattern of bleeding in a large prospective cohort of haemophilia A patients: A three‐year follow‐up of the AHEAD (Advate in HaEmophilia A outcome Database) study

G. Spotts, J. Oldenburg, C. Hermans, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Individualizing prophylaxis in hemophilia: a review

L. Valentino, P. Petrini, A. Gringeri, 2015, Expert review of hematology.

Long-term aspects of hemophilia B treatment: part II

A. Gringeri, 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A

P. Cortesi, L. Mantovani, K. Steinitz, 2017, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Use of prophylaxis to prevent complications of hemophilia.

P. Mannucci, A. Gringeri, L. Mendolicchio, 2001, Advances in experimental medicine and biology.

Recombinant full‐length factor VIII (FVIII) and extended half‐life FVIII products in prophylaxis – new insight provided by pharmacokinetic modelling

K. Steinitz, A. Gringeri, M. Wolfsegger, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Haemophilia prophylaxis: how can we justify the costs?

A. Willan, M. Carcao, W. Schramm, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Real World Prospective Data on Bleeding Frequency in 1,000 Patients with Hemophilia a - is the Goal of Zero Bleeds Achievable?

J. Oldenburg, K. Khair, K. Kurnik, 2017 .

Eliminating parvovirus B19 from blood products

M. Morfini, E. Santagostino, A. Azzi, 1994, The Lancet.

Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1--infected patients (the EURIS study).

Z. Bentwich, A. Burny, E. Santagostino, 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Guidelines for Treatment of Patients with Hemophilia and Inhibitors

A. Gringeri, 2005 .

Quality of life in haemophilia

A. Gringeri, S. von Mackensen, S. Mackensen, 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

A 10-year, randomized, clinical trial on prophylaxis vs. on-demand treatment in children with haemophilia A: the E.S.P.R.I.T. study

L. Mantovani, A. Gringeri, P. Mannucci, 2008 .

Recommendations for reporting economic evaluations of haemophilia prophylaxis: a nominal groups consensus statement on behalf of the Economics Expert Working Group of The International Prophylaxis Study Group

L. Mantovani, A. Willan, M. Carcao, 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[Quality of life of young patients with haemophilia in Europe].

M. Bullinger, A. Gringeri, S. von Mackensen, 2008, Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz.

Immunogenicity of a recombinant hepatitis B vaccine in hemophiliacs

A. Zanetti, M. Morfini, N. Ciavarella, 1988, American journal of hematology.

A prospective, randomized, and crossover study of an activated prothrombin complex concentrate for secondary prophylaxis in patients with hemophilia A and inhibitors (Pro-FEIBA): subject demographics and safety data

C. Leissinger, C. Négrier, E. Berntorp, 2010 .

Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100°C heat after lyophilization

M. Morfini, E. Santagostino, P. Mannucci, 1997 .

Joint Disease and the Potential for Improved Joint Health in Inhibitor Patients Who Have a Good Response to aPCC Prophylaxis: Data From the Profeiba Study

P. Cortesi, L. Valentino, C. Leissinger, 2012 .

P. Cortesi, L. Mantovani, C. Leissinger, 2012 .

Comparison of attitudes towards prenatal diagnosis and termination of pregnancy for haemophilia in Iran and Italy

M. Karimi, A. Gringeri, P. Mannucci, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Cost of Illness Analysis of Hemophilia A: Resources Use and Direct Costs in Italy

M. L. Specchia, M. Morfini, G. Torre, 2011 .

Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products

P. Cortesi, L. Mantovani, M. Rota, 2017, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Development and Pilot testing of a Disease-Specific Quality of Life Questionnaire for Adult Patients with Haemophilia (Haem-A-QoL).

A. Gringeri, S. Mackensen, 2004 .

Primary and secondary prophylaxis in children with haemophilia A reduces bleeding frequency and arthropathy development compared to on-demand treatment : a 10-year, randomized, clinical trial

L. Mantovani, A. Gringeri, P. Mannucci, 2009 .

Differences between patients’, physicians’ and pharmacists’ preferences for treatment products in haemophilia: a discrete choice experiment

L. Mantovani, L. Scalone, A. Gringeri, 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

PSY47 Evaluating the Cross-over Effect on Health-related Quality of Life in a Randomized Cross-over Study of Hemophilia-A Patients

P. Cortesi, L. Mantovani, C. Leissinger, 2011 .

A randomized clinical trial on prophylaxis vs. episodic treatment in children with haemophilia A: the ESPRIT study

L. Mantovani, A. Gringeri, P. Mannucci, 2010 .

Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.

M. Morfini, E. Santagostino, P. Mannucci, 1997, Transfusion.

Treatment protocol of haemophilia and other congenital bleeding disorders in Italy

C. Kessler, A. Gringeri, U. Martinowitz, 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

Development of an inhibitor-specific questionnaire for the assessment of health-related quality of life in haemophilia patients with inhibitors (INHIB-QoL)

J. Oldenburg, K. Khair, S. Riva, 2013 .

Long-term immunogenicity of a plasma-derived hepatitis B vaccine in HIV seropositive and HIV seronegative hemophiliacs.

E. Tanzi, A. Zanetti, M. Morfini, 1989, Archives of internal medicine.

The use of recombinant factor VIII in the management of Hemophilia

A. Gringeri, P. Mannuccio Mannucci, 1991, Current studies in hematology and blood transfusion.

Striving for a Bleed Free World - An Interim Analysis from the AHEAD Study

J. Oldenburg, K. Khair, K. Kurnik, 2016 .

Meta-Analysis on Incidence of Inhibitors in 1,945 Previously Untreated Patients Treated with Recombinant Factor VIII Products: Is There a Difference?

P. Cortesi, L. Mantovani, M. Rota, 2015 .

Chapter 58. Quality of Life in Hemophilia

A. Gringeri, Sylvia von Mackensen PhD Senior Scientist Visiting Scientist, 2010 .

PHM5 ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HAEMOPHILIA WITH THE NEWLY DEVELOPED HAEMOPHILIA-SPECIFIC INSTRUMENT HAEM-A-QOL

L. Mantovani, L. Scalone, A. Gringeri, 2005 .

The knowledge and perception of factor concentrate in persons with haemophilia A

P. Mannucci, D. Brettler, A. Gringeri, 1995, Haemophilia : the official journal of the World Federation of Hemophilia.

IFN alpha kinoid vaccine in conjunction with tritherapy, a weapon to combat immunopathogenesis in AIDS.

A. Gringeri, A. Lachgar, B. Bizzini, 1999, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS.

V Chams, A Lachgar, A. Burny, 1998, Proceedings of the National Academy of Sciences of the United States of America.

Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-alpha immunization: a 30-month follow-up report.

A. Burny, E. Santagostino, P. Mannucci, 1996, Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology.

Evidence for an antiviral effect and interferon neutralizing capacity in human sera; variability and implications for HIV infection.

E. Santagostino, A. Gringeri, H. Le Coq, 1995, Cellular and molecular biology.

Anti-alpha interferon immunization: safety and immunogenicity in asymptomatic HIV positive patients at high risk of disease progression.

E. Santagostino, P. Mannucci, A. Gringeri, 1995, Cellular and molecular biology.

A randomized, placebo-controlled, blind anti-AIDS clinical trial : safety and immunogenicity of a specific anti-IFNα immunization

A. Burny, E. Santagostino, P. Mannucci, 1994 .

Suboptimal response to hepatitis B vaccine in drug users.

A. Zanetti, P. Mannucci, A. Boschini, 1991, Archives of internal medicine.

Immunogenicity of a yeast‐recombinant hepatitis B vaccine in high‐risk children

M. Colombo, P. Mannucci, A. Gringeri, 1989, Journal of medical virology.

Prevalence of pancreatic disorders in HIV-infected hemophiliacs: diagnostic methods and their clinical significance.

E. Santagostino, P. Mannucci, A. Gringeri, 1994, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Serum hepatitis B virus DNA detects cryptic hepatitis B virus infections in multitransfused hemophilic patients

G. Colucci, P. Mannucci, A. Gringeri, 1990 .

Patterns of Immunogenicity of an Inactivated Hepatitis A Vaccine in Anti-HIV Positive and Negative Hemophilic Patients

A. Zanetti, E. Santagostino, A. Rocino, 1994, Thrombosis and Haemostasis.

Defective nef alleles in a cohort of hemophiliacs with progressing and nonprogressing HIV-1 infection.

F. Veglia, E. Santagostino, E. Vicenzi, 1999, Virology.

Abnormalities of lymphocyte subsets are correlated with concentrate consumption in asymptomatic Italian hemophiliacs treated with concentrates made from American plasma

A. Gringeri, D. Mari, P. Mannucci, 1984, American journal of hematology.

National survey of human immunodeficiency virus infection in Italian hemophiliacs: 1983–1987

P. Mannucci, A. Gringeri, Medical-Scientific Committee of the Fondazione dell’Emofilia, 1988, La Ricerca in clinica e in laboratorio.

Hemophilia and nonprogressing human immunodeficiency virus type 1 infection.

A. Lazzarin, A. Mantovani, E. Santagostino, 1997, Blood.

HIV ANTIGEN AND VIRUS-SAFETY STUDIES

G. Mariani, A. Gringeri, P. Mannucci, 1988, The Lancet.

Susceptibility to HIV infection and AIDS in Italian haemophiliacs is HLA associated

A. Gringeri, P. Mannucci, M. Marchini, 1990, British journal of haematology.

[HIV-related thrombocytopenias].

P. Mannucci, A. Gringeri, 2000, Annali italiani di medicina interna : organo ufficiale della Societa italiana di medicina interna.

Possible association of HLA-DR2 phenotype and detectable human immunodeficiency virus (HIV) p24 antigen in HIV-positive patients.

A. Gringeri, M. Marchini, G. Fabio, 1993, The Journal of infectious diseases.

P. Pontisso, M. Morfini, E. Santagostino, 1997, Blood.

C-C chemokines, pivotal in protection against HIV type 1 infection.

S. O’Brien, A. Burny, E. Santagostino, 1998, Proceedings of the National Academy of Sciences of the United States of America.

A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A.

K. Shianna, D. Goldstein, J. Goedert, 2013, Human molecular genetics.

Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors.

E. Fenyö, A. Gringeri, Å. Björndal, 1997, The Journal of infectious diseases.

High-purity factor VIII concentrates produced without using monoclonal antibodies

P. Mannucci, A. Gringeri, M. Cattaneo, 1990, La Ricerca in clinica e in laboratorio.

Erratum: Therapeutic choices for patients with hemophilia and high-titer inhibitors (American Journal of Hematology (2001) 67 (240-246))

M. Poon, L. Aledort, E. Berntorp, 2002 .

Anti-LAV and Concentrate Consumption in Italian Hemophiliacs

P. Mannucci, A. Zanetti, D. Geroldi, 1985, Thrombosis and Haemostasis.

Anti-LAV/HTLV-III antibodies in groups of individuals at high risk for infection in Italy

P. Mannucci, A. Zanetti, G. Zehender, 1985, La Ricerca in clinica e in laboratorio.

Pushing the frontiers of medicine: innovations in haemophilia care

G. Spotts, L. Valentino, A. Gringeri, 2014 .

Short-term Exposure to High Altitude Causes Coagulation Activation and Inhibits Fibrinolysis

P. Mannucci, G. Mariani, P. Mannucci, 2002, Thrombosis and Haemostasis.

Comparative analysis of marketed factor VIII products: recombinant products are not alike vis‐a‐vis soluble protein aggregates and subvisible particles

C. Lubich, B. Reipert, A. Gringeri, 2018, Journal of Thrombosis and Haemostasis.

Prevalence of HTLV‐IIVLAV antibodies in Italian asymptomatic hemophiliacs given commercial concentrates of factors VIII and IX

F. Mandelli, G. Mariani, P. Mannucci, 1986, Journal of medical virology.

Anti-IFNα immunization raises the IFNα-neutralizing capacity of serum — an adjuvant to antiretroviral tritherapy

A. Burny, E. Santagostino, J. Zagury, 1999 .

Anti-IFN alpha immunization raises the IFN alpha-neutralizing capacity of serum--an adjuvant to antiretroviral tritherapy.

A. Burny, E. Santagostino, J. Zagury, 1999, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

The multiple benefits of sport in haemophilia

A. Gringeri, S. von Mackensen, A. Farrugia, 2018, Haemophilia.

Cost-Effectiveness of Prophylaxis with Anti-Inhibitor Complex Concentrate in Patients with Hemophilia A and Inhibitors: Results From the Pro-FEIBA Study,

P. Cortesi, L. Mantovani, C. Leissinger, 2011 .

Antibody to hepatitis C virus (anti-HCV) in hemophiliacs: A study with a second generation immunoenzymatic assay (ELISA)

A. Gringeri, M. Colombo, M. Rumi, 1991 .

Hepatitis C virus (HCV) coinfection in a cohort of HIV positive long-term non-progressors: possible protective effect of infecting HCV genotype on HIV disease progression.

A. Lazzarin, E. Santagostino, E. Vicenzi, 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Biological effect of active anti-IFN alpha immunization in HIV-infected patients.

A. Burny, E. Santagostino, A. Gringeri, 1995, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Biological effect of active anti-IFNα immunization in HIV-infected patients

A. Burny, E. Santagostino, A. Gringeri, 1995 .

Is there a difference in inhibitor incidence with recombinant products? A meta-analysis of 2000 previously untreated patients

P. Cortesi, L. Mantovani, K. Trošt, 2016 .

Adverse Effects of Treatment with Porcine Factor VIII

P. Giangrande, E. Santagostino, A. Gringeri, 1991, Thrombosis and Haemostasis.

Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP‐induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor

A. Gringeri, P. Mannucci, M. Cattaneo, 1994, British journal of haematology.

C1 inhibitor function and anti-C1 inhibitor autoantibodies in patients with HIV type 1 infection.

M. Cicardi, A. Gringeri, A. Agostoni, 1999, AIDS research and human retroviruses.